[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atezolizumab\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atezolizumab":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100614423","trimpact-real-world-first-line-atezolizumab-use-in-stage-iv-nsclc-with-pd-l1-50-100614423",false,"NCT07279402","TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%","TRIMPACT: A Prospective Real-World Study of Atezolizumab Monotherapy as First-Line (Stage IV) Treatment in Patients With Non-Small Cell Lung Cancer With PD-L1 Tumor Cell Expression ≥50% and No Targetable Mutations","Inclusion Criteria:\n\n* Signed informed consent form.\n* Diagnosis of stage IV non-small cell lung cancer.\n* Male or female patients aged 18 years or older.\n* Patients who have been prescribed atezolizumab in accordance with routine clinical practice and the locally approved indication in Türkiye.\n* Patients who have received up to 3 cycles of atezolizumab at the screening visit.\n\nExclusion Criteria:\n\n* Patients who are not receiving atezolizumab for the treatment of lung cancer according to standard of care and the approved indication.\n* Known or suspected hypersensitivity to atezolizumab.\n* Pregnant or breastfeeding women.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.",[24,25,26,27],"NSCLC Stage IV","PD-L1 Gene Mutation","Atezolizumab","Real World Study",[29],"NSCLC, PD-L1, Atezolizumab, Real World","RECRUITING","2026-04-29",{"date":33,"type":34},"2026-04-30","ACTUAL",{"date":36,"type":34},"2025-09-15",{"date":38,"type":20},"2027-10-01",{"name":40,"class":41},"Antalya Training and Research Hospital","OTHER_GOV",25,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100562953","dtace-haic-combined-with-bevacizumab-and-atezolizumab-for-huge-hepatocellular-carcinoma-100562953","NCT06609863","dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma","dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Intermediate and Advanced Hepatocellular Carcinoma: a Prospective Phase II Study","Inclusion Criteria:\n\n1. Clinical diagnosis of HCC.\n2. Age between 18 and 75 years;\n3. The maximum tumor size ≥10 cm;\n4. Intermediate-advanced huge HCC, advanced HCC with PVTT type I-III\n5. limited metastases (≤5).\n6. Child-Pugh class A or B;\n7. Eastern Cooperative Group performance status (ECOG) score of 0-1;\n8. Hemoglobin ≥ 8.5 g\u002FdL Total bilirubin ≤ 30mmol\u002FL Serum albumin ≥ 32 g\u002FL ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT\u002FAPTT within normal limits Absolute neutrophil count (ANC) \\>1,500\u002Fmm3\n9. Prothrombin time ≤18s or international normalized ratio \\\u003C 1.7.\n10. Ability to understand the protocol and to agree to and sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Diffuse HCC;\n2. Extrahepatic metastasis \\>5;\n3. Obstructive PVTT involving mesenteric vena cava (PVTT IV).\n4. Serious medical comorbidities.\n5. Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy\n6. untreated or incompletely treated esophageal or gastric varices (assessed with esophagogastroduodenoscopy) with bleeding or high risk of bleeding.\n7. Eastern Cooperative Group performance status (ECOG) score of ≥2;\n8. Known or suspected allergy to the investigational agents or any agent given in association with this trial.\n9. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy\n10. Evidence of bleeding diathesis.\n11. Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.","75 Years",{"count":52,"type":20},27,"INTERVENTIONAL",[55],"NA","This study intends to evaluate the efficacy and safety of drug-eluting transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (dTACE-HAIC) plus Bevacizumab and Atezolizumab for patients with intermediate-advanced huge hepatocellular carcinoma.",[58,26,59,60],"Advanced Hepatocellular Carcinoma","Bevacizumab","Chemotherapy",[62,26,59],"hepatocellular carcinoma","2024-12-01",{"date":65,"type":34},"2024-12-03",{"date":67,"type":34},"2024-10-01",{"date":69,"type":20},"2026-06-30",{"name":71,"class":72},"Sun Yat-sen University","OTHER",1]